6.39
-0.93%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Changzhou Qianhong Biopharma Co
Its shares trade on Shenzhen under the ticker 002550.SZ. It has been listed since 18 February 2011. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.57bn and net income of CN¥398.8m. At that date it held total assets of CN¥3.09bn and shareholders' equity of CN¥2.77bn.
Changzhou Qianhong Biopharma Co., Ltd. engages in the research and development, production, and sale of bio-pharmaceutical products. The company is headquartered in Changzhou, Jiangsu. The company went IPO on 2011-02-18. The firm mainly provides liquaemin sodium raw materials and preparations, applied to prevent and treat thromboembolism desease; kallidinogen preparations, applied in the treatment of micro-circulation disorder disease, asparaginase bulk drugs and preparations, applied in the treatment of acute lymphoblastic leukemia, as well as compound digestive enzyme capsules II. The firm distributes its products within domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Feb 2011
- Employees
- 1,102
- Website
- qhsh.com.cn ↗
Leadership
Pay as last reported
- Mr. Yaofang WangChairman of the Board, since 2008CN¥1.4m
- Mr. Gang ZhaoVice Chairman of the Board, since 2008CN¥1.2m
- Mr. Yi YaoFinance Director, Secretary of the Board
- Mr. Ke WangGeneral Manager, Director, since 2017
- Mr. Chizhou JiangDeputy General Manager, Director, since 2024
- Mr. Xiang ZhouDeputy General Manager, Director, since 2024
- Mr. Tao HaiDeputy General ManagerCN¥300,000
- Ms. Jie HuangGeneral Director
- Mr. Chunwei MeiGeneral Director
- Mr. Guming WangGeneral Director
- Mr. Lijun WeiGeneral Director
- Ms. Hongping YeGeneral Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Changzhou Qianhong Biopharma employs 1102 employees in the Health Care sector.
- The company produces liquaemin sodium raw materials for thromboembolism treatment.
- Changzhou Qianhong Biopharma offers kallidinogen preparations for micro-circulation disorders.
Weaknesses
- The company has no international headquarters outside Changzhou, China.
- Changzhou Qianhong Biopharma lacks a global distribution network.
- Changzhou Qianhong Biopharma's products are limited to domestic and overseas markets.
Opportunities
- Changzhou Qianhong Biopharma can expand into the global Pharmaceuticals market.
- The company can leverage its 1102 employees for R&D growth.
- Changzhou Qianhong Biopharma can target acute lymphoblastic leukemia treatments.
Threats
- Changzhou Qianhong Biopharma faces competition from domestic pharmaceutical companies.
- The company's reliance on the domestic market poses a risk.
- Changzhou Qianhong Biopharma must comply with Chinese pharmaceutical regulations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.